

Special Issue

Epstein-Barr Virus Infection in Cancer

Message from the Guest Editors

Epstein-Barr virus (EBV) has been found to be associated with different malignancies. Various studies have described the *in vitro* transforming ability of EBV, mostly attributed to properties of its latent proteins. However, increasing evidence points to a role of the early lytic genes in the transforming event. Interestingly, only a few viral genes are expressed in the tumours; thus, it is still unclear what the exact role of the other viral proteins in the pathogenesis and the maintenance of EBV-associated malignancies is, and whether EBV could use a “hit-and-run” mechanism. Also, how the infection contributes to the Myc-IGH translocation remains largely unknown. Furthermore, the specific geographical distribution of some EBV-associated malignancies indicates that their development requires different environmental and genetic co-factors; currently, only some of these are known. With this Special Issue, we aim to further elucidate the role of EBV in cancer, addressing some of these still open questions.

Guest Editors

Prof. Dr. Lorenzo Leoncini
Dr. Lucia Mundo
Dr. Rosita Accardi-Gheit

Deadline for manuscript submissions

closed (30 June 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/36206

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)